« Return to News | Drug Sponsors

Boston Scientific launches Interlock

Thursday, June 30, 2011 01:25 PM

Boston Scientific has launched its Interlock-35 Fibered IDC Occlusion System in the U.S. and Europe.  Earlier this year, the system received clearance from the FDA and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

The Interlock-35 System consists of a 0.035" detachable coil with an interlocking connection between the coil and delivery wire designed to offer placement control, including the ability to advance, retract and reposition the coil before final deployment in the vessel.  The coil is engineered to be detached by simply pushing the detachment zone beyond the distal end of the 5F delivery catheter.  The platinum coil is constructed with a network of synthetic fibers, designed to offer thrombogenicity (blockage of blood flow) and rapid stasis.

The Interlock-35 Fibered IDC Occlusion System is available in 31 configurations that include coil lengths from 4cm to 40cm, diameters from 3mm to 20mm, and three distinct shapes (cube, 2D helical and diamond) to offer physicians greater flexibility to treat diverse vessel anatomy.  When combined with Boston Scientific's 0.018" Interlock Fibered IDC Coils, the Interlock Coil portfolio provides 50 different coils to optimize peripheral embolization procedures.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.